Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Low Testosterone Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT01403116
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate, topical testosterone gel
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jun 11, 2026, 9:35 AM EDT
Terminated Phase 2 Interventional Results available

Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

NCT00957034
View directory record Official record
Conditions
Heart Failure
Interventions
placebo, testosterone
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Lakewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jun 11, 2026, 9:35 AM EDT
Withdrawn Phase 4 Interventional

Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes

NCT00440440
View directory record Official record
Conditions
Hypogonadism, Diabetes
Interventions
Testosterone gel, placebo
Drug
Lead sponsor
Diabetes Center of the Southwest
Other
Eligibility
35 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Midland, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jun 11, 2026, 9:35 AM EDT
Completed No phase listed Observational Results available

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

NCT03063125
View directory record Official record
Conditions
Bladder Cancer, Low Testosterone Levels
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

NCT01187485
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androderm® 2.5mg, Androderm® 5.0mg, Androderm® 7.5mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

NCT01816295
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone Solution, Placebo Solution
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Homewood, Alabama • Chandler, Arizona • Glendale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 2 Interventional

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

NCT01386567
View directory record Official record
Conditions
Hypogonadism, Low Testosterone
Interventions
Androxal (enclomiphene citrate), Testim (topical testosterone)
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Jun 11, 2026, 9:35 AM EDT
Withdrawn Phase 3 Interventional

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

NCT02082197
View directory record Official record
Conditions
Hypogonadism, Testosterone Deficiency
Interventions
ABT-SLV176
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

NCT00413244
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AndroGel 5 Grams, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993212
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
8
States / cities
Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

NCT00141492
View directory record Official record
Conditions
Type 2 Diabetes, Hypogonadism
Interventions
Androgel (testosterone gel)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
70
States / cities
Birmingham, Alabama • Calera, Alabama • Mobile, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2015 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 2 Interventional

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

NCT00163566
View directory record Official record
Conditions
Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Drug
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
55 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Testopel ® vs. Generic Testosterone Pellets.

NCT04523480
View directory record Official record
Conditions
Hypogonadism
Interventions
Testopel 75mg Drug Implant, Testopel 100mg Drug Implant, Testopel 200mg Drug Implant
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Results available

Opioid Antagonism in Hypogonadotropic Hypogonadism

NCT04975334
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Low Testosterone
Interventions
Naloxone
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Testosterone Replacement in Older Men and Atherosclerosis Progression

NCT00287586
View directory record Official record
Conditions
Hypogonadism, Atherosclerosis
Interventions
Testosterone Gel (Androgel), Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years and older · Male only
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

NCT01201863
View directory record Official record
Conditions
Endocrine Dysfunction, Trauma, Brain Injury
Interventions
Androgel (Testosterone Gel), Placebo gel
Drug · Other
Lead sponsor
Craig Hospital
Other
Eligibility
16 Years to 65 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jun 11, 2026, 9:35 AM EDT
Not yet recruiting Phase 4 Interventional

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

NCT04601233
View directory record Official record
Conditions
Multiple Sclerosis, Erectile Dysfunction, Testosterone Deficiency
Interventions
XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 3 Interventional

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00349791
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Jun 11, 2026, 9:35 AM EDT
Active, not recruiting Phase 2 Interventional

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

NCT04049331
View directory record Official record
Conditions
Hypogonadism, Male, Fatigue Syndrome, Chronic
Interventions
Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo
Drug · Other
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 54 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Not applicable Interventional

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

NCT00392912
View directory record Official record
Conditions
Alzheimer's Disease, Hypogonadism
Interventions
AndroGel (Solvay Pharmaceuticals)
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
55 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Optimizing Protein Intake in Older Americans With Mobility Limitations

NCT01275365
View directory record Official record
Conditions
Mobility Limitation
Interventions
Testosterone enanthate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jun 11, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men

NCT02697188
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone undecanoate, Testosterone enanthate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Jun 11, 2026, 9:35 AM EDT
Withdrawn Phase 4 Interventional

Testosterone and Pain Sensitivity

NCT01689896
View directory record Official record
Conditions
Low Testosterone, Hypogonadism, Pain
Interventions
Testosterone Gel, Placebo Gel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jun 11, 2026, 9:35 AM EDT